Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial

NCT03520985 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03520985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
October 1, 2018
Completion date
February 3, 2021
Enrollment
34 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma